Taken together, these results indicate that inhibition of the pyrimidine synthesis pathway by targeting the β-Catenin/CBP signaling nodule represents a viable therapeutic option to treat TMPRSS2-ERG/GOF p53 mutant-positive PCa. Here, TMPRSS2 is linked to posterior cortical atrophy.